Role of Reactive Oxygen Species in the Abrogation of Oxaliplatin Activity by Cetuximab in Colorectal Cancer

Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment andRASMutations in Colorectal Cancer

(2015) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics

(2014) Carlos L. Arteaga et al.   CANCER CELL

Association of EGFR Expression Level and Cetuximab Activity in Patient-Derived Xenograft Models of Human Non-Small Cell Lung Cancer

(2014) C. Amendt et al.   CLINICAL CANCER RESEARCH

mTOR Co-Targeting in Cetuximab Resistance in Head and Neck Cancers Harboring PIK3CA and RAS Mutations

(2014) Zhiyong Wang et al.   JNCI-Journal of the National Cancer Institute

Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial

(2014) John Primrose et al.   LANCET ONCOLOGY

Caspase-Independent Cell Death Is Involved in the Negative Effect of EGF Receptor Inhibitors on Cisplatin in Non-Small Cell Lung Cancer Cells

(2013) H. Yamaguchi et al.   CLINICAL CANCER RESEARCH

Modulation of oxidative stress as an anticancer strategy

(2013) Chiara Gorrini et al.   NATURE REVIEWS DRUG DISCOVERY

Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

(2013) Jean-Yves Douillard et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study

(2012) Kjell Magne Tveit et al.   JOURNAL OF CLINICAL ONCOLOGY

Cetuximab-mediated Tumor Regression Depends on Innate and Adaptive Immune Responses

(2012) Xuanming Yang et al.   MOLECULAR THERAPY

Erlotinib-Mediated Inhibition of EGFR Signaling Induces Metabolic Oxidative Stress through NOX4

(2011) K. P. Orcutt et al.   CANCER RESEARCH

EGFR Nuclear Translocation Modulates DNA Repair following Cisplatin and Ionizing Radiation Treatment

(2011) G. Liccardi et al.   CANCER RESEARCH

Cisplatin induces production of reactive oxygen species via NADPH oxidase activation in human prostate cancer cells

(2011) Tomohiro Itoh et al.   FREE RADICAL RESEARCH

Up-regulation and Sustained Activation of Stat1 Are Essential for Interferon-γ (IFN-γ)-induced Dual Oxidase 2 (Duox2) and Dual Oxidase A2 (DuoxA2) Expression in Human Pancreatic Cancer Cell Lines

(2011) Yongzhong Wu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

(2011) Timothy S Maughan et al.   LANCET

IFNγ mediates DUOX2 expression via a STAT-independent signaling pathway

(2010) Thomas Hill et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

The relationship between cisplatin-induced reactive oxygen species, glutathione, and BCL-2 and resistance to cisplatin

(2010) Anamaria Brozovic et al.   CRITICAL REVIEWS IN TOXICOLOGY

Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer

(2010) Marc Peeters et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

(2010) Jean-Yves Douillard et al.   JOURNAL OF CLINICAL ONCOLOGY

Understanding resistance to EGFR inhibitors—impact on future treatment strategies

(2010) Deric L. Wheeler et al.   Nature Reviews Clinical Oncology

Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines

(2009) Laetitia Dahan et al.   BRITISH JOURNAL OF PHARMACOLOGY

Oxidative epithelial host defense is regulated by infectious and inflammatory stimuli

(2009) Monica Valencia Gattas et al.   FREE RADICAL BIOLOGY AND MEDICINE

Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation

(2008) D Balin-Gauthier et al.   BRITISH JOURNAL OF CANCER

The EGFR-STAT3 Oncogenic Pathway Up-regulates the Eme1 Endonuclease to Reduce DNA Damage after Topoisomerase I Inhibition

(2008) A. Vigneron et al.   CANCER RESEARCH

Nox1 is over-expressed in human colon cancers and correlates with activating mutations in K-Ras

(2008) Eunice Laurent et al.   INTERNATIONAL JOURNAL OF CANCER

Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

(2008) Rafael G. Amado et al.   JOURNAL OF CLINICAL ONCOLOGY

Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

(2008) Carsten Bokemeyer et al.   JOURNAL OF CLINICAL ONCOLOGY

EGFR Antagonists in Cancer Treatment

(2008) Fortunato Ciardiello et al.   NEW ENGLAND JOURNAL OF MEDICINE

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE